AssetMark’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.95K Buy
+20
New +$1.88K ﹤0.01% 3060
2026
Q2
– Sell
-345
Closed -$27.3K – 3627
2026
Q1
$27.3K Buy
345
+20
+6% +$1.62K ﹤0.01% 1950
2025
Q4
$26.7K Hold
325
– – ﹤0.01% 1912
2025
Q3
$22.7K Hold
325
– – ﹤0.01% 1877
2025
Q2
$20.8K Hold
325
– – ﹤0.01% 1795
2025
Q1
$20.6K Hold
325
– – ﹤0.01% 1700
2024
Q4
$21.6K Hold
325
– – ﹤0.01% 1634
2024
Q3
$22.7K Hold
325
– – ﹤0.01% 1473
2024
Q2
$21.1K Buy
+325
New +$20.6K ﹤0.01% 1382
2016
Q3
– Sell
-30
Closed -$1K – 1264
2016
Q2
$1K Sell
30
-22
-42% -$863 ﹤0.01% 1135
2016
Q1
$2K Hold
52
– – ﹤0.01% 1073
2015
Q4
$3K Buy
+52
New +$2.57K ﹤0.01% 1048

Other funds holding PBE

AssetMark's PBE Position: Q3 2026 in Review

AssetMark opened a new position in Invesco Biotechnology & Genome ETF (PBE) in Q3 2026: 20 shares worth $1.95K. The stake represents ﹤0.01% of the portfolio and ranks #3060 among its holdings. This is a return to the name: AssetMark previously reported a position in PBE as recently as Q1 2026.

AssetMark first reported a position in PBE in Q4 2015 and has held it in 12 quarters since. The position peaked at $27.3K in Q1 2026. 106 funds tracked by Wall St. Rank hold PBE as of Q3 2026.

  • AssetMark held 20 shares of Invesco Biotechnology & Genome ETF worth $1.95K as of Q3 2026.
  • Invesco Biotechnology & Genome ETF was a new AssetMark position in Q3 2026.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3060 holding.
  • AssetMark first reported a position in Invesco Biotechnology & Genome ETF in Q4 2015 and has held it in 12 quarters since.
  • AssetMark's Invesco Biotechnology & Genome ETF position peaked at $27.3K in Q1 2026.
  • 106 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.